Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China,International Journal of Hypertension

当前位置： X-MOL 学术 › Int. J. Hypertens. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Hypertension May Reduce the Infection Risk but Increase the Severity of COVID-19: Based on the Current Data in China
International Journal of Hypertension ( IF 1.9 ) Pub Date : 2021-12-20 , DOI: 10.1155/2021/6594863
Bo Li _{1,

2} , Lu Zeng ₃ , Nengjun Sun ₄ , Yunhe Zhao _{1,

2} , Faming Zhao ₅ , Hongjun Bian ₆ , Wei Yi ₇ , Jing Yang ₈ , Bin Li _{9,

10} , Guohai Su _{9,

10}

Affiliation

Department of Cardiology, Shandong University Zibo Central Hospital, No. 10, South Shanghai Road, Zibo 255000, China.
Department of Cardiology, Zibo Hospital Affiliated to Shandong First Medical University, Zibo, Shandong 255000, China.
Weifang Medical University, No. 288, Shengli East Street, Weifang City, Shandong 261000, China.
Department of Medical Administration, Shandong University Central Hospital of Zibo, No. 54, Gong Qing Tuan Xi Road, Zibo 255036, China.
Department of Infectious Diseases, No. 4, Hospital of Zibo, No. 210, Shan Quan Road, Zibo 255000, China.
Departments of Emergency Medicine, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250012, China.
Department of Intelligent Manufacturing Teaching, Engineering Training Center, Shandong University, Jinan 250002, China.
Binzhou Medical University, No. 346, Guanhai Road, Laishan District, Yantai 264003, China.
Department of Cardiology, Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong,250013, China.
Department of Cardiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong 250013, China.

Increasing evidence has shown an unusual relationship between hypertension and COVID-19, which may not be as simple as previously thought. The purpose of our study was to determine the association of hypertension with the onset and development of COVID-19. A meta-analysis was performed to summarize the prevalence of hypertension in COVID-19 patients, as well as the usage of ACEIs/ARBs. Metaregression analyses were used to evaluate the association of hypertension with disease severity and mortality. PubMed and Google Scholar were searched for relevant studies. A total of 42 studies including 14138 patients were enrolled in the study. The proportion of hypertension in COVID-19 patients in China was 17.7% according to the enrolled studies, while it was 6.0% in a study containing 72314 confirmed cases, which are both much lower than in the general population. All of the data from the 11 provinces in China showed the same tendency. The proportions of hypertension were higher in severe/ICU patients and nonsurvivors than in nonsevere/ICU patients and survivors. The metaregression analyses suggested that both disease severity and risk of death were associated with the incidence of hypertension. A total of 27.6% of COVID-19 patients with hypertension received ACEI/ARB therapy. The proportion of deaths in COVID-19 patients with hypertension treated with ACEIs/ARBs was significantly lower than that in nonuse patients treated with ACEIs/ARBs. In conclusion, hypertension may reduce the infection risk of COVID-19 but increase the risk of developing worse clinical outcomes. The use of ACEIs/ARBs may benefit COVID-19 patients with hypertension.

更新日期：2021-12-20

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南

全部期刊列表>>